Results 211 to 220 of about 19,474 (223)

GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients

Journal of Cancer Research and Clinical Oncology, 2021
Lin Danna, Li-Hua Yang, Lung-Ji Chang
exaly  

Disialoganglioside GD2 as a therapeutic target for human diseases

Expert Opinion on Therapeutic Targets, 2015
Maya Suzuki
exaly  

Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma

British Journal of Cancer, 2008
Barbara Carlini, Alberto Garaventa, Maria Valeria Corrias   +2 more
exaly  

The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting

British Journal of Cancer, 2012
Uta Dirksen, Claudia Rossig, Bianca Altvater   +2 more
exaly  

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults

Pediatric Blood and Cancer, 2016
Irene Y Cheung, Irina Ostrovnaya
exaly  

Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma

Cancer, 2014
Jonathan Gill, Richard G Gorlick, Michael E Roth   +2 more
exaly  

Effect of Gd2 O3 Dispersion on the Thermal Conductivity of UO2

Journal of Nuclear Science and Technology, 2009
Yuji Arita, Tsuneo Matsui, Takanori Nagasaki   +2 more
exaly  

ASC amino acid transporter 2, defined by enzyme-mediated activation of radical sources, enhances malignancy of GD2-positive small-cell lung cancer

Cancer Science, 2018
Masahide Takahashi, Koichi Furukawa, Atsushi Enomoto   +2 more
exaly  

GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells

Cellular and Molecular Life Sciences, 2010
Hye Jin Jin, Soo Jin Choi, Seong Who Kim
exaly  

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response

Cancer Immunology, Immunotherapy, 2013
Christiane A. Helm, Nikolai Siebert, Holger Lode   +2 more
exaly